U.S. License Holder:
AstraZeneca UK Ltd.
Date of License:
IMFINZI (durvalumab) is a programmed death-ligand 1 (PD-L1) blocking antibody indicated:
For the treatment of adult patients with locally advanced or metastatic urothelial carcinoma who: Have disease progression during or following platinum-containing chemotherapy; Have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy;
For the treatment of adult patients with unresectable, Stage III non-small cell lung cancer (NSCLC) whose disease has not progressed following concurrent platinum-based chemotherapy and radiation therapy;
In combination with etoposide and either carboplatin or cisplatin, as first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC).
U.S. Patent LitigationsPACER
U.S. Patent Nos.
9,402,899 (Immunopotentiative Composition)
Bristol-Myers Squibb Co.; E.R. Squibb and Sons LLC; Ono Pharmaceutical Co., Ltd.; Tasuku Honjo
AstraZeneca Pharmaceuticals LP; AstraZeneca UK Limited